16679-58-6 Usage
Description
Desmopressin (Brand name: DDAVP) is an artificial derivative of vasopressin, being similar to the antidiuretic hormone (ADH) that naturally produced in the body. It is used for the treatment of diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease and high blood urea levels. It is capable of increasing the water permeability in the renal tubular cells, further increasing the urine concentration and decreasing the urine production. Therefore, it can be used to prevent and control severe thirst, urination and dehydration caused by various kinds of reasons including injury, surgery and certain medical condition. This help you sleep throughout the night without being awaken by urinate.
References
https://www.drugbank.ca/drugs/DB00035
http://www.medicinenet.com/desmopressin_tabs/article.htm
https://en.wikipedia.org/wiki/Desmopressin
Chemical Properties
White or almost white, fluffy powder.
Originator
DAV,Ritter,Switz.,1974
Uses
Different sources of media describe the Uses of 16679-58-6 differently. You can refer to the following data:
1. Antidiuretic.
2. [deamino-Cys1, D-Arg8]-Vasopressin acetate salt hydrate was used to study the impact of vasopressin on pendrin abundance. E3 ubiquitin (Ub)-protein ligases (E3s) was administered in rat kidney and the changes in protein abundance of the selected E3s in response to [deamino-Cys1, D-Arg8]-Vasopressin acetate salt hydrate was examined.
Definition
ChEBI: A synthetic analogue of vasopressin in which 3-mercaptopropionic acid replaces the cysteine residue at position 1 and D-arginine replaces the residue at position 8. An antidiuretic, it increases urine concentration and decreases urine prod
ction, and is used (usually as the trihydrate of the acetic acid salt) to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions. It is also used in the diagnosis and treatment of cranial
iabetes insipidus and in tests of renal function.
Manufacturing Process
β-Benzylmercaptopropionyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-Lasparaginyl-S-benzyl-L-cysteinyl-L-prolyl-NG-tosyl-D-arginyl-glycinamide (0.5
g) is reduced with sodium in liquid ammonia. The liquid ammonia is then
evaporated and the residue dissolved in 5% aqueous acetic acid (800 ml). The
solution is filtered to remove the undissolved portion and the filtrate is
adjusted to a pH of 6.5 to 7 by addition of aqueous sodium hydroxide and it is
then oxidized by known procedure, cf. Kimbrough, R.D., Jr.; Cash, W.D.;
Branda, L.A.; Chan, W.Y.; and Du Vigneaud, V.; J. Biol. Chem. 238,1411
(1963). The reaction mixture is thereupon adjusted to a pH of 4 to 4.5 by
addition of acetic acid. The peptide is applied to a column of a carboxylate ion
exchange resin, is eluted with 50% aqueous acetic acid and isolated by
lyophilization (freeze-drying). The crude product is purified by known
procedure using a carrier-free high-voltage electrophoresis, cf. Zaoral, M.;
Sorm, F.; Collection Czechoslov. Chem Communs, 31, 310 (1966). Yield, 100
to 200 mg of 1-deamino-8-D-argine-vasopressin.
Brand name
Concentraid (Ferring Pharmaceuticals); Ddavp
(Sanofi Aventis); Stimate (ZLB Behring).
Therapeutic Function
Antidiuretic
Biochem/physiol Actions
[deamino-Cys1, D-Arg8]-Vasopressin acetate salt hydrate also known as DDAVP, Desmopressin is a selective and potent vasopressor agent that stabilizes the cardiocirculatory function in normal human as well as in patients suffering from catecholamine-resistant vasodilatory shock. It also stimulate three acid-base transporters and hence increases the capability of the cell to regulate pH.
Clinical Use
Diabetes insipidusNocturnal enuresisNocturia due to idiopathic nocturnal polyuriaPost-biopsy bleeding (unlicensed indication)Pre-biopsy prophylaxis (unlicensed indication)
Drug interactions
Potentially hazardous interactions with other drugsNone known
Metabolism
Metabolic fate of desmopressin is unknown. It is not
affected by liver microsomal cytochrome P450 enzymes.
As a peptide, desmopressin is expected to undergo
catabolism to its constituent amino acids, with subsequent
recycling of the amino acid in the body pool.
Check Digit Verification of cas no
The CAS Registry Mumber 16679-58-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,6,7 and 9 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 16679-58:
(7*1)+(6*6)+(5*6)+(4*7)+(3*9)+(2*5)+(1*8)=146
146 % 10 = 6
So 16679-58-6 is a valid CAS Registry Number.
InChI:InChI=1/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
16679-58-6Relevant articles and documents
Cyclic Peptide Formation in Reduced Solvent Volumes via In-Line Solvent Recycling by Organic Solvent Nanofiltration
Ormerod, Dominic,Noten, Bart,Dorbec, Matthieu,Andersson, Lars,Buekenhoudt, Anita,Goetelen, Ludwig
, p. 841 - 848 (2015/07/27)
Cyclic peptides have found numerous and wide ranging applications that include drug molecules, nanomaterials, and chiral chromatography stationary phases. However, in the crucial cyclization step, high dilution conditions are often required, resulting in large volumes of solvent being consumed to prepare relatively small quantities of product. This paper demonstrates the synthesis of a cyclic nonapeptide with in-line solvent recycling via organic solvent nanofiltration (OSN) resulting in a significant reduction in the solvent load of the reaction and concomitant improvement in process mass intensification (PMI). The membrane was used to remove the reaction product from the reaction vessel, as the cyclic peptide product shows limited stability in the presence of an excess of reaction reagent. In comparison to the standard batch reaction, no loss in yield or product purity was observed for the OSN process tested. The proof-of-concept study outlined in this paper was performed on a real active pharmaceutical ingredient (API), and the technique used is widely applicable and flexible.